UNSPSC 51391705: Bambuterol

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y1850G1OVC. European Medicines Agency schedules Bambuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06095MIG. Bambuterol generally arises in the molecular formula C18H29N3O5.

UNSPSC 51391705 Bambuterol is a Commodity code that, based on recent state and local solicitations, encompasses pharmaceutical products and related health-support systems procured by public health agencies and state departments. The recent opportunities under this code reflect procurement of naloxone and drug deactivation systems for community health initiatives, as well as broader pharmacy benefit program management and direct-to-manufacturer prescription fulfillment. State and local governments buying under this code include county health departments and state health and human services agencies; issuing bodies to date include Seminole County, Florida and the Texas Health and Human Services Commission.

Recent activity shows two distinct procurement approaches. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS, posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries an initial two-year term with a one-year renewal option and includes FEMA funding. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription programs for the state's pharmacy benefit initiative, seeking vendor experience with direct contracting for self-insured employers and outcomes-based agreements. Geographic concentration appears limited to Florida and Texas in the recent record; the code shows moderate activity but the two opportunities reflect divergent procurement strategies—one for specific pharmaceutical products and one for pharmacy program infrastructure and vendor partnerships.